In early August 2020, Mayo Clinic researchers reported that blood plasma donated from individuals who had recovered from COVID-19, was helpful despite a lack a formal data to support its use. In October 2020, a study on the use of convalescent plasma to treat moderate COVID-19 illness in adults reported that this treatment was not effective in reducing the progression to severe disease or preventing COVID-19 related deaths. In 2021, the FDA revised the authorization for convalescent plasma and limited its use to high-titer convalescent plasma for early treatment of hospitalized patients or in persons with impaired humoral immunity who are unable to produce an adequate antibody response. Low-titer convalescent plasma was declared ineffective and its use was no longer authorized.
IMPORTANT NOTE: NVIC encourages you to become fully informed about COVID-19 and the COVID-19 vaccine by reading all sections in the table of contents, which contains many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.
